MedAdvisor Past Earnings Performance
Past criteria checks 0/6
MedAdvisor has been growing earnings at an average annual rate of 17%, while the Healthcare Services industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 37.6% per year.
Key information
17.0%
Earnings growth rate
33.3%
EPS growth rate
| Healthcare Services Industry Growth | 42.6% |
| Revenue growth rate | 37.6% |
| Return on equity | -8.3% |
| Net Margin | -4.5% |
| Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
Recent updates
Benign Growth For MedAdvisor Limited (ASX:MDR) Underpins Stock's 35% Plummet
Mar 20
The Market Doesn't Like What It Sees From MedAdvisor Limited's (ASX:MDR) Revenues Yet As Shares Tumble 27%
Feb 03MedAdvisor Limited (ASX:MDR) Held Back By Insufficient Growth Even After Shares Climb 26%
Dec 07Lacklustre Performance Is Driving MedAdvisor Limited's (ASX:MDR) Low P/S
Oct 23Is MedAdvisor (ASX:MDR) Using Too Much Debt?
Jun 26Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S
Apr 24Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?
Mar 20Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?
Dec 15Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?
Apr 20MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt
Jun 29Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now
Nov 09Is MedAdvisor (ASX:MDR) A Risky Investment?
Oct 11Is MedAdvisor (ASX:MDR) Using Too Much Debt?
Mar 08MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain
Feb 10What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?
Jan 18
The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares
Dec 22What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?
Dec 18Revenue & Expenses Breakdown
How MedAdvisor makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 24 | 104 | -5 | 13 | 0 |
| 30 Sep 24 | 113 | -2 | 14 | 0 |
| 30 Jun 24 | 122 | 1 | 15 | 0 |
| 31 Mar 24 | 116 | -4 | 15 | 0 |
| 31 Dec 23 | 109 | -9 | 15 | 0 |
| 30 Sep 23 | 104 | -10 | 14 | 0 |
| 30 Jun 23 | 98 | -11 | 13 | 0 |
| 31 Mar 23 | 96 | -8 | 10 | 0 |
| 31 Dec 22 | 93 | -5 | 7 | 0 |
| 30 Sep 22 | 80 | -11 | 5 | 0 |
| 30 Jun 22 | 68 | -17 | 3 | 0 |
| 31 Mar 22 | 66 | -16 | 3 | 0 |
| 31 Dec 21 | 64 | -14 | 3 | 0 |
| 30 Sep 21 | 52 | -14 | 3 | 0 |
| 30 Jun 21 | 39 | -14 | 3 | 0 |
| 31 Mar 21 | 28 | -13 | 4 | 0 |
| 31 Dec 20 | 18 | -12 | 6 | 0 |
| 30 Sep 20 | 14 | -11 | 6 | 0 |
| 30 Jun 20 | 10 | -10 | 6 | 0 |
| 31 Mar 20 | 9 | -9 | 5 | 0 |
| 31 Dec 19 | 9 | -9 | 4 | 0 |
| 30 Sep 19 | 9 | -8 | 5 | 0 |
| 30 Jun 19 | 8 | -8 | 5 | 0 |
| 31 Mar 19 | 8 | -7 | 5 | 0 |
| 31 Dec 18 | 7 | -7 | 5 | 0 |
| 30 Sep 18 | 7 | -6 | 5 | 0 |
| 30 Jun 18 | 7 | -4 | 4 | 0 |
| 31 Mar 18 | 6 | -4 | 4 | 0 |
| 31 Dec 17 | 6 | -4 | 4 | 0 |
| 30 Sep 17 | 5 | -4 | 4 | 0 |
| 30 Jun 17 | 4 | -3 | 3 | 0 |
| 31 Mar 17 | 3 | -4 | 2 | 0 |
| 31 Dec 16 | 2 | -4 | 2 | 0 |
| 30 Sep 16 | 2 | -4 | 1 | 0 |
| 30 Jun 16 | 1 | -3 | 1 | 0 |
| 31 Mar 16 | 1 | -2 | 1 | 0 |
| 31 Dec 15 | 2 | -1 | 1 | 0 |
| 30 Sep 15 | 2 | -1 | 1 | 0 |
| 30 Jun 15 | 2 | -1 | 0 | 0 |
| 30 Jun 14 | 1 | -1 | 0 | 0 |
Quality Earnings: MDR is currently unprofitable.
Growing Profit Margin: MDR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MDR is unprofitable, but has reduced losses over the past 5 years at a rate of 17% per year.
Accelerating Growth: Unable to compare MDR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDR is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (15.5%).
Return on Equity
High ROE: MDR has a negative Return on Equity (-8.3%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/09 05:25 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MedAdvisor Limited is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anubhav Saxena | Bell Potter |
| Thomas Wakim | Bell Potter |
| Elyse Shapiro | Canaccord Genuity |